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Abstract
Background
Idiopathic Parkinson disease (PD) is a common neurodegenerative disease that seriously
hinders limb activities and affects patients’ lives. We performed a meta-analysis aiming to
systematically review and quantitatively synthesize the efficacy and safety of traditional Chi-
nese medicine (TCM) as an adjunct therapy for clinical PD patients.
Methods
An electronic search was conducted in PubMed, Cochrane Controlled Trials Register,
China National Knowledge Infrastructure, Chinese Scientific Journals Database and Wan-
fang data to identify randomized trials evaluating TCM adjuvant therapy versus convention-
al treatment. The change from baseline of the Unified Parkinson’s Disease Rating Scale
score (UPDRS) was used to estimate the effectiveness of the therapies.
Results
Twenty-seven articles involving 2314 patients from 1999 to 2013 were included. Potentially
marked improvements were shown in UPDRS I (SMD 0.68, 95%CI 0.38, 0.98), II (WMD
2.41, 95%CI 1.66, 2.62), III (WMD 2.45, 95%CI 2.03, 2.86), IV (WMD 0.32, 95%CI 0.15,
049) and I-IV total scores (WMD 6.18, 95%CI 5.06, 7.31) in patients with TCM plus dopa-
mine replacement therapy (DRT) compared to DRT alone. Acupuncture add-on therapy
was markedly beneficial for improving the UPDRS I–IV total score of PD patients (WMD
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10.96, 95%CI 5.85, 16.07). However, TCMmonotherapy did not improve the score. The ef-
fectiveness seemed to be more obvious in PD patients with longer adjunct durations. TCM
adjuvant therapy was generally safe and well tolerated.
Conclusions
Although the data were limited by methodological flaws in many studies, the evidence indi-
cates the potential superiority of TCM as an alternative therapeutic for PD treatment and
justifies further high-quality studies.
Background
Parkinson’s disease (PD) is the second most common progressive neurodegenerative disorder
worldwide; it is caused by progressive loss of dopaminergic neurons in the substantia nigra and
features physical signs including distal resting tremor, bradykinesia, rigidity, asymmetric onset
and non-motor symptoms [1]. However, the exact etiology and pathogenesis of PD remains
elusive [2]. In Mainland China, the prevalence of PD over age of 65 years is 1.7% with a rising
trend annually [3]. However, no treatment is available to effectively slow down or halt PD pro-
gression [4]. Dopamine replacement therapy (DRT) is still the most effective symptomatic
strategy, and levodopa is the only drug that has been reported availably to extend life expectan-
cy [5]. After long-term DRT usage, however, the therapeutic effects become increasingly less
beneficial, and more than 50% of patients eventually experience highly disabling fluctuations,
dyskinesia and agonist-induced sleep attacks [6–9]. In traditional Chinese medicine (TCM),
PD symptom was first described as shaking palsy by Huangdi Neijing (ca. 100 A.D.), and TCM
has exerted an indispensable effect in medical care of PD patients for thousands of years. Good
compliance for long-term use with few side effects may be the foremost merits of TCM. Re-
cently, a meta-analysis demonstrated that Chinese Herb Medicine (CHM) adjuvant therapy
improved the clinical symptom severity scores of PD patients with few adverse effects com-
pared to Western Conventional Medication (WCM) controls [10]. TCM is a holistic system of
medicine including herbal medicine, acupuncture, moxibustion, Tai Chi, tuina, dietary therapy
and qigong. With unique theories of diagnosis and treatment, TCM emphasizes overall treat-
ment concepts based on syndrome differentiation. Up to 2013, a considerable number of clini-
cal trials examining the role of TCM in PD treatment have been performed. The goal of the
present study was to assess the efficacy and safety of TCM in PD treatment and to provide ad-
ditional treatment options for PD patients.
Materials and Methods
Data Sources and Search Strategies
We undertook a systematic review to identify randomized clinical trials of TCM that were pub-
lished before October 2013. A research protocol was drafted and approved by the faculty mem-
bers. For the literature review, we searched PubMed, Cochrane Controlled Trials Register
(CCTR), China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Data-
base (VIP), andWanfang data. The search strategies were used as the cross-referenced TCM/
Chinese herbal medicine (CHM) and its proprietary names with Parkinson disease, including
“zhong yi” (Chinese medicine), “zhong yao” (Chinese herbs), “zhong yi yao” (traditional Chi-
nese medicine), “zhong cheng yao” (Chinese patent medicine), “zhong cao yao” (Chinese herbal
TCM as Adjunct Therapy in PD Treatment
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medicine),“zhen ci” (acupuncture), “zhen jiu” (acupuncture and moxibustion), “zhong xi yi jie
he” (integrated traditional Chinese and western medicine), “an mo” (massage), “tui na” (tuina),
“qi gong” (Qigong), “gua sha” (skin scraping therapy), “ba guan” (cupping), “Parkinson’s”,
“Parkinson disease”, and “Parkinson’s complication”. No language restriction was applied. Un-
published trials were not included. These journals all publish peer-reviewed manuscripts with
open access.
Inclusion Criteria
(1) Types of studies: Randomized controlled trials (RCTs) lasting for at least 12 weeks
were included.
(2) Types of participants: Participants were at Hoehn and Yahr (H&Y) stages 1–4 and were
of any age or sex with idiopathic PD diagnosed according to the UK Brain Bank criteria
[11], Chinese National Diagnosis Standard (CNDS) of 1984 [12] or the CNDS updated
version of 2006 [13].
(3) Types of interventions: TCMs (herbal medicine, patent medicine, acupuncture, moxibus-
tion, tuina, dietary therapy, qigong and other folk therapies) and Chinese medicine inte-
grated with conventional medicine were included if detailed data were available. In all,
interventions were any form of TCMs in any dose alone or as adjunct treatment for PD or
PD-related complications. Comparisons between different types of TCMs were excluded.
(4) Types of outcome measures: In addition to the obligatory measurement index of the Uni-
fied Parkinson’s Disease Rating Scale (UPDRS) score, following standards of outcome de-
tection might also be included: the British 39-item Parkinson's Disease Questionnaire
(PDQ- 39); Parkinson's Disease Quality of Life Questionnaire (PDQL), Webster scale,
H&Y staging, adverse events rate, and others. The UPDRS scale is the most commonly
used standard consisting of the following four segments: part I (mentation, behavior and
mood) addresses mental dysfunction and mood; part II (activities of daily living, ADL) as-
sesses physical function status; part III (motor section) evaluates motor impairment; and
part IV (complications) assesses treatment related motor and non-motor complications.
Exclusion criteria
Quasi-randomized controlled trials, randomized crossover trials, case reports, reviews, and
studies concerning secondary Parkinsonism, cell culture or animal experiments were excluded.
Case series or clinical trials regarding the efficiency and safety of TCM on PD were also exclud-
ed if they 1) included an inappropriate diagnosis standard for PD; 2) had a treatment course
lasting less than 12 weeks; 3) did not use the UPDRS score as the outcome measure; 4) were
unverified RCT studies; and 5) were duplicate publications.
Data Extraction and Analysis
The authors (GXZ, NX and ZTZ) independently scanned the titles and abstracts of studies for
eligibility and relevance. Potentially relevant papers were retrieved and reviewed for selection
according to the inclusion and exclusion criteria. Any discrepancies were resolved by discus-
sion (95% level of agreement) or further evaluated by the third author (TW). For rigorous data
collection, a standard data extraction form was used and the items recorded included the au-
thors, year of publication, type of study, participants (sample size, gender proportion, age and
TCM as Adjunct Therapy in PD Treatment
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dropouts), diagnostic criteria, outcome measures, TCM/placebo intervention, side effects, labo-
ratory examination, effective rate and results.
Quality Assessment (risk of bias)
The risk of bias in relation to the study quality was independently evaluated by two authors
(GXZ and ZTZ). Disagreements were resolved by discussion, and a level of 95% agreement was
achieved. According to the Cochrane Collaboration’s risk of bias assessment tool, items that re-
ferred to the assessment of the risk of bias for studies might be related to the method of ran-
domization, concealment of treatment allocation, blinding of patients, researchers and
assessors (intervention, data collection and analysis), outcome measures (completeness of out-
come data, selective report of outcomes, adequacy of follow-up, and parallel between cases and
controls) and any other potential sources of bias.
Data Synthesis and Analysis
To evaluate the TCM efficiency in controlling PD symptoms versus placebo comprehensively,
we synthesized the results in a meta-analysis. Fixed-effect model or random-effect model
would be used based on heterogeneity in different trials. Weighted mean difference (WMD)
with 95% confidence intervals (CI) was calculated for continuous data using RevMan 5.2 soft-
ware. Heterogeneity was tested using a standard chi-square test and I2 statistic. Two-tailed P
values less than 0.05 were considered statistically significant. Funnel plot analysis and egger’s
test were used to detect Publication Bias.
Results
Study selection
By searching CCTR, PubMed, CNKI, VIP, and Wanfang data, we obtained 1789 trials that
were potentially relevant to the research project. After reading titles and abstracts of the arti-
cles, 1345 trials were excluded due to irrelevant information. For the remaining 444 articles, we
performed an overall evaluation, analyzed the full text, and then excluded 417 studies. Finally,
27 papers [14–40] were included in this systematic review. The screening process is summa-
rized in a flow diagram (Fig. 1).
Characteristics of Included Studies
Of the 27 articles included, 14 employed the 1984 PD diagnostic criteria, 4 used the 2006 PD
diagnosis standards (CNDS version updated in 2006), and 9 followed the UK Brain Bank diag-
nostic criteria. No patient in H&Y stage 5 was included. Except for two studies [26,27] that em-
ployed acupuncture, participants in the treatment groups were managed with herbal medicine
in the remaining 25 studies, among which two studies [18,20] used TCM as monotherapy and
23 applied TCM plus western medicine as treatment methods.
Among the 27 included studies with a total of 2314 participants (1169 in the treatment
group vs. 1145 in the control group), 26 articles demonstrated no significant difference at base-
line in gender, age and other basic information. One study, however, reported a distribution
difference regarding gender, but with no significant difference observed [33]. Most studies
were limited to 12 weeks but in 6 articles the treatment durations lasted for 13 [25] and 24
weeks [17,19, 27,33,40]. Detailed baseline information of the 27 studies is presented in S1
Table. Sixteen articles [14–18,20,22–24,27–31,38,39] described the dosage and frequency of
routine therapy. Twenty-five articles reported a clinical curative effect with marked improve-
ment in mental and emotional states, behavioral and daily activities and motor functions of
TCM as Adjunct Therapy in PD Treatment
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patients as assessed by the UPDRS and other scales, and two trials [18,20] compared TCM
alone to Madopar or benzhexol. In toto, 15 studies evaluated the effectiveness of TCM on non-
motor symptoms, of which 4 trials reported more effectiveness of TCM on non-motor symp-
toms than on motor symptoms based on a statistically significant difference (S2 Table). More-
over, 15 articles performed laboratory tests of liver and kidney function and performed
electrocardiogram (ECG) experiments showing no obvious abnormalities. Side effects were re-
ported in eight studies [20,22,25,29,31,33,36,37] with 75 vs. 105 person-time (treatment group
vs. control group), including diarrhea, nausea, constipation, dry mouth, stomachache, sialor-
rhea, hypotension, insomnia and depression. Most side effects in the TCM group were relative-
ly mild, occurred less frequently and were less severe than those in the western medicine group
and always disappeared after decrement or discontinuation of the drugs. However, three trials
reported a high adverse effect frequency in both the treatment and control groups (13 vs. 24
person-time [22], 46 vs. 35 person-time [36], and 17 vs. 29 person-time [37]). The study char-
acteristics are summarized in S3 Table. Of the two articles [26,27] that examined acupuncture
and included a total of 98 participants, an improvement was obvious in the acupuncture thera-
py group. Yang et al. [27] reported that acupuncture plus routine treatment yielded an 89.4%
improvement in preventing and controlling PD symptoms in comparison to a 52.6% improve-
ment for routine treatment alone. All characteristics of the included studies are summarized in
Table 1.
Risk of Bias of Included Studies
The Cochrane Collaboration’s risk of bias assessment tool was used to assess the risk of bias.
Items evaluated included random allocation, concealment schemes, similarity at baseline, pla-
cebo, blinding, drop-out, intention-to-treat analysis, acceptable compliance, cross-over trials,
and selective reports. Thirteen trials [14,18,24,27,28,30–34,36,38,40] described the stochastic
Fig 1. Flow diagram for process of identifying eligible randomized controlled trials.RCT: randomized
controlled trials; TCM: Traditional Chinese Medicine; H&Y: Hoehn & Yahr.
doi:10.1371/journal.pone.0118498.g001
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Table 1. Data summary and characteristics of the 27 studies included in meta-analysis.
Author
(year)
Intervention Laboratory
examination
Outcome
Measures
Clinical effect rate Adverse effect (n)
Control group
(drug/ dosage /
frequency)
Treatment group
(drug/ dosage /
frequency)
Treatment
group
Control
group
Treatment
group
Control group
Wang
et al.
2013
[20]
Benzhexol 1–2mg,
bid
Kangzhen Zhijing
Capsule, 15 tables/d
U UPDRS 88% 52% 3 8
Zhang
et al.
2013
[18]
Madopar, 125mg,
tid-qid; Chinese
herb placebo
Bushen Huoxue
Granule, bid; Madopar,
125mg, tid-qid; placebo
Y UPDRS,
the TCM
symptom
scale
77.80% 81.40% N N
Zhao
et al.
2013
[33]
Western medicine
(N/A); placebo
Western medicine (N/
A); Guling Pa’an
Granul, 6g, tid
Y UPDRS III U U 3 2
Li et al.
2012
[21]
sinemet/madopar
(N/A)
sinemet/madopar (N/A);
Jiawei Zhichan
Decoction once daily
U Sleep
scale,
UPDRS
U U U U
Zhong
et al.
2012
[26]
Madopar; previous
dosage
Moxibustion, qd,3
times/week; Madopar
previous dosage
U UPDRS, H-
Y, Webster,
ADL
93.30% 63.30% U U
Zhong
et al.
2012
[35]
Western medicine
(N/A)
Western medicine (N/
A); Bushen Huoxue
Tongluo Capsule
U UPDRS,
LSIB,
PDQ39
U U U U
Kum
et al.
2011
[25]
Western medicine
(N/A); placebo
Western medicine (N/
A); Jia Wei Liu Jun Zi
Tang
U UPDRS-IV,
PDQ-39,
SF-36,
GDS,
DSQS
U U mild diarrhea:
1
N
Pan
et al.
2011
[40]
Western medicine
(N/A); placebo
Western medicine (N/
A); Zeng-xiao An-shen
Zhi-chan2
Y UPDRS II/
III/IV, ADL
improved No
improvement
N N
Zheng
et al.
2011
[16]
Madopar,
125–250mg, tid;
placebo
Madopar, 125–250mg,
tid; Bushen constant
vibration, qd
Y UPDRS,
H-Y
46.67% 16.67% N N
Fan
et al.
2010
[30]
Madopar, 125mg,
tid
Madopar, 125mg, tid;
Pabing Recipe II once
daily
U UPDRS 46.67% 16.67% U N
Yang
et al.
2010
[31]
Madopar,
375–1000mg/d;
placebo
BushenHuoxue
Granules, bid;Madopar
375–1000mg/d
Y UPDRS III,
muscle
tension
U U 2 6
Yuan
et al.
2010
[36]
Western medicine
(N/A)
Western medicine
(N/A); Shudi Pingchan
Decoction
Y UPDRS II,
UPDRS III,
H&Y
43.33 16.67 GC: 14;
Constipation:
22
GC:10;
Constipation:25
Jiang
et al.
2009
[22]
Madopar
<750mg/d
Madopar <750mg/d;
Guiling Pa'an Pill, tid
U UPDRS 86.66% 63.33% 13 person-
time
24 person-time
(Continued)
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Table 1. (Continued)
Author
(year)
Intervention Laboratory
examination
Outcome
Measures
Clinical effect rate Adverse effect (n)
Control group
(drug/ dosage /
frequency)
Treatment group
(drug/ dosage /
frequency)
Treatment
group
Control
group
Treatment
group
Control group
Zhao
et al.
2009
[34]*
Madopa/sinemet
(N/A); placebo
Madopar/sinemet (N/A);
Guiling Pa’an Capsule
Y UPDRS
total/ II/ III
76.23% 68.30% U U
Zhao
et al.
2009
[34]&
placebo Guiling Pa’an Capsule Y UPDRS
total/ II/ III
67.86% 52% U U
Zhao
et al.
2009
[34]#
Madopar/sinemet
(N/A); placebo
Madopar/sinemet (N/A);
Guiling Pa’an Capsule
Y UPDRS
total/ II / III
78.67% 70.89% U U
Zhu
et al.
2009
[19]
Western medicine
(N/A)
Western medicine
(N/A); Dingzhen tang,
bid
U UPDRS III,
autonomic
function
U U U U
Lian
et al.
2008
[39]
Madopar, 125mg,
tid; placebo
Madopar,125mg tid;
Jiaweiguizhijiagegen-
tang
Y UPDRS U U N N
Liang
et al.
2008
[29]
Madopar,
125–250mg, tid-
qid; Trastal, 50mg,
bid
Madopar, 125–250mg,
tid-qid; Five Zhui feng
powder, qd
Y UPDRS 86.67% 70% N 1
Shen
et al.
2008
[17]
Madopar
467 ± 164 mg/ d
Madopar 442 ± 149
mg/d; Tongxinluo
Capsule, 9 pills/d;
Liuwei Rehmannia
Root Pill 24 pills/d
U UPDRS III U U U U
Zhang
et al.
2008
[23]
Madopar,125mg,
tid; placebo
Madopar,125mg,tid;
Dingzhen Decoction,
qd
U UPDRS U U U U
Zhang
et al.
2008
[24]
Madopar, 125mg/d Madopar 125mg/d;
Pabing Recipe I/II
Y UPDRS,
H-Y
86.67% 70% N N
Lian
et al.
2007
[38]
Madopar, 125mg,
tid; placebo
Madopar, 125mg, tid;
Pabing Recipe I/III, qd
Y UPDRS-I/II/
III/IV/total
Pabing
Recipe I
95.5%; III
100%
91.80% N N
Luo
et al.
2007
[32]
Madopar (N/A) Madopar (N/A); Pabing
Recipe I
U UPDRS U U U U
Shen
et al.
2006
[37]
Western medicine
(N/A)
Western medicine (N/
A); Chinese herb
medicine
Y UPDRS II/
III, Webster
75 6.3 Vomit: 5;
Constipation:
8; Mouth
dry: 4
Vomit: 11;
Constipation:
13; Mouth dry: 5
Yang
et al.
2006
[27]
Madopar, 62.5–
500mg, bid-qid
Madopar, 62.5–500mg,
bid-qid; Acupuncture,
qod
U UPDRS 89.40% 52.60% U U
(Continued)
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methods in detail including simple random sampling [14,24,30,32], random number table ran-
dom sampling [18,27,28,38], online random grouping [31,33], random numbers [40], and SAS
statistical software [34,36]. Six trials [15,25,31,33,36,40] mentioned allocation concealment, in-
cluding a central telephone randomization system [31,33], coded containers [25,40], and sealed
envelopes [15,36]. Seven studies [18,25,28,31,33,34,40] were designed with blind methods in-
cluding single blind [18,28] and double blind [25,31,33,34,40] methods. All included studies
were parallel, and participants were assessed before and after therapy. However, only nine stud-
ies reported relevant information regarding follow-up, of which five trials stated that 74 partici-
pants [25,31,33,34,40] from both groups eventually left the study, and four trials [27,30,37,38]
indicated no dropouts, while the remaining 20 trials failed to mention withdrawal information.
One trial [25] stated their utilization of an intention-to-treat analysis (ITT), and two trials
[31,33] reported sample size estimation methods, while the others merely mentioned the num-
ber of participants (Table 2).
Synthesis of Results
Among the 27 selected trials, two [26,27] assessed acupuncture plus conventional therapy vs.
conventional therapy alone, one [34] assessed TCM vs. a placebo, two [18,20] assessed TCM vs.
Western drugs, and 23 evaluated the effect of TCM plus western drugs vs. western therapy alone,
of which 9 [14,16,23,30,32,35,38–40], 12 [14,16,23,29,30,32,34–36,38–40], 14 [14,16,19,23,29–
32,34–36,38–40], 10 [14,16,23,25,30,32,35,38–40], and 10 [15,21,22,28,32,34,36–38,40] estimated
the treatment effect using the UPDRS-I, UPDRS-II, UPDRS-III, UPDRS-IV, and UPDRS-total
scores, respectively.
Table 1. (Continued)
Author
(year)
Intervention Laboratory
examination
Outcome
Measures
Clinical effect rate Adverse effect (n)
Control group
(drug/ dosage /
frequency)
Treatment group
(drug/ dosage /
frequency)
Treatment
group
Control
group
Treatment
group
Control group
Zheng
et al.
2006
[14]
Madopar,
125–250mg, tid
Madopar, 125–250mg,
tid; Pabing Recipe III,
once daily
Y UPDRS,
H-Y
43.33% 16.67% N N
Wang
et al.
2004
[15]
Madopar,
125–250mg, bid;
basic therapy (N/
A); Placebo
Ziyin Xifeng Huoxue
Decoction, qd; basic
therapy (N/A)
Y UPDRS 80% 75.50% N N
Zhang
et al.
2004
[28]
Madopar(475.0
±320.5)mg;
Placebo
Madopa(425.5±296.2)
mg; naokangning
capsule, 3 pills, tid
Y UPDRS,
SF-36,
PDTCMS
76.67% 60% N N
U: Unclear; Y: yes; N: No; GC: gastrointestinal complaints; UPDRS: uniﬁed Parkinson disease rating scale; H-Y: Hoehn and Yahr; ADL: Activities of daily
living; LSIB: Life Stisfction lnex B; PDQ39: Parkinson’s Disease Questionnaire-39; SF-36: Short Form-36 Health Survey; PDTCMS: Parkinson’s Disease
Traditional Chinese Medicine scale; GDS: Geriatric Depression Scale; DSQS: Deﬁciency of Spenic Qi Scale. N/A: no detailed information.
*: H&Y stages 4 with Madopar-taking history;
&: H&Y stages 1–4 without Madopar-taking history;
#: H&Y stages 1–3 with Madopar-taking history.
doi:10.1371/journal.pone.0118498.t001
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TCM plus western drugs vs. western therapy alone
UPDRS-I.Nine trials [14,16,23,30,32,35,38–40] compared the effect of TCM plus Western
drugs versus Western drugs alone according to changes in the UPDRS-I score. Ten trials
showed mild heterogeneity in the consistency of the trial results (chi-square = 21.85, P = 0.009;
I2 = 59%). Therefore, a random effects model was used for statistical analysis. A meta-analysis
showed a significant beneficial effect of TCM as an adjuvant compared to Western drugs alone
in improving the UPDRS-I score (SMD 0.68 [0.38, 0.98]; Z = 4.44, P< 0.00001). The effect
contributed to controlling the symptoms of mentation, behavior and mood in PD patients
(Fig. 2A). The funnel plot was roughly symmetric (Fig. 2B). However, Egger’s test indicated
publication bias existed (P = 0.000).
UPDRS-II. Twelve studies [14,16,23,29,30,32,34–36,38–40] showed homogeneity in the
consistency of the trial results (chi-square = 10.98, P = 0.61; I2 = 0%). A fixed effects model was
used. Compared to conventional treatment alone, TCM plus conventional therapy significantly
decreased the UPDRS-II scores (WMD 2.41, [1.66, 2.62]; Z = 8.71, P< 0.00001), which indi-
cated that TCMmight improve the activities of daily life in PD patients (Fig. 3A). The funnel
plot was symmetric (Fig. 3B). Egger’s test indicated no publication bias (P = 0.670).
UPDRS-III. Fourteen independent trials [14,16,19,23,29–32,34–36,38–40] showed mild
heterogeneity in the consistency of the results (chi-square = 25.23, P = 0.07; I2 = 37%). Thus, a
fixed effects model was applied. The statistical analysis indicated that adjuvants TCMs were
Fig 2. TCM plus western drugs VS. western therapy alone: UPDRS I score. (A) Forest plot of comparison. NO.1: Pabing Recipe I; NO.3: Pabing
Recipe III. (B) Funnel plot of comparison.
doi:10.1371/journal.pone.0118498.g002
Fig 3. TCM plus western drugs VS. western therapy alone: UPDRS II score. (A) Forest plot of comparison. NO.1: Pabing Recipe I; NO.3: Pabing
Recipe III; *: H&Y stages 4 with Madopar-taking history; #: H&Y stages 1–3 with Madopar-taking history. (B) Funnel plot of comparison.
doi:10.1371/journal.pone.0118498.g003
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more beneficial than routine methods in alleviating the UPDRS-III score, specifically for motor
function (WMD 2.45 [2.03, 2.86]; Z = 11.57, P< 0.00001) (Fig. 4A). The funnel plot was sym-
metric (Fig. 4B). Egger’s test indicated no publication bias (P = 0.630).
UPDRS-IV. Ten studies [14,16,23,25,30,32,35,38–40] showed homogeneity in the results
(chi-square = 9.78, P = 0.46; I2 = 0%). A fixed-effects model was used. Compared to conven-
tional treatment, CHM adjuvant therapy significantly improved the UPDRS IV scores (WMD:
0.32, [0.15, 049]; Z = 3.69, P = 0.0002), suggesting that CHM adjuvant therapy contribute to
improving complications of treatment in patients with PD (Fig. 5A). The funnel plot was sym-
metric (Fig. 5B). Egger’s test indicated no publication bias (P = 0.788).
UPDRS I–IV total. Ten trials [15,21,22,28,32,34,36–38,40] showed homogeneity in the trial
results (chi-square = 8.93, P = 0.54; I2 = 0%). Therefore, a fixed effects model was applied for
statistical analysis. The results showed a significant beneficial effect of TCM as an adjuvant
therapy in improving the UPDRS-total score (WMD: 6.18 [5.06, 7.31]; Z = 10.79, P<0.00001),
suggesting that TCM as an adjuvant therapy markedly improve the symptoms of PD patients
(Fig. 6A). The funnel plot was symmetric (Fig. 6B). Egger’s test indicated no publication bias
(P = 0.586).
Fig 4. TCM plus western drugs VS. western therapy alone: UPDRS III score. (A) Forest plot of comparison. NO.1: Pabing Recipe I; NO.3: Pabing
Recipe III; *: H&Y stages 4 with Madopar-taking history; #: H&Y stages 1–3 with Madopar-taking history. (B) Funnel plot of comparison.
doi:10.1371/journal.pone.0118498.g004
Fig 5. TCM plus western drugs VS. western therapy alone: UPDRS IV score. (A) Forest plot of comparison. NO.1: Pabing Recipe I; NO.3: Pabing
Recipe III. (B) Funnel plot of comparison.
doi:10.1371/journal.pone.0118498.g005
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Acupuncture plus Madopar vs. Madopar alone
Two trials [26,27] evaluated Madopar with or without acupuncture as an adjuvant therapy. No
heterogeneity was found (chi-square = 0.94, P = 0.33; I2 = 0%). Consequently, a fixed model
was applied. Acupuncture as an adjuvant therapy combined with Madopar was markedly bene-
ficial in improving the UPDRS I–IV total score in PD patients (WMD: 10.96, [5.85, 16.07];
Z = 4.21, P<0.0001) (S1 Fig.).
TCM vs. placebo
TCM vs. placebo treatment of PD was tested in one study [34]. Compared with the placebo,
TCM showed significant improvement in the UPDRS-III score [MD 2.1, (-0.98, 5.18)] (S2A
Fig.) and the UPDRS I-IV total score [MD 2.57, (-2.37, 7.51)] (S2B Fig.).
TCM vs. Western drugs
TCM vs. Western drugs were tested in 2 trials [18,20]. Compared with Madopar, Bushen
Huoxue Granules alone did not improve PD symptoms according to the UPDRS I-IV total
score [MD-2.3, (-4.1, -0.50)] [18] (S3 Fig.). Similarly, compared with benzhexol, Kangzhen
Zhijing capsules alone did not improve the UPDRS-II/III score (data not shown).
Side effects
Eight studies involving side effect showed mild heterogeneity in the consistency of the results
(chi-square = 17.76, P = 0.01; I2 = 61%). A random-effects model was used for statistical analy-
sis. A statically significant improvement was shown in the RR (0.62, [0.40, 0.96], P (Z) = 0.03),
suggesting that CHM adjuvant therapy significantly reduce side effects caused by conventional
medicine (Fig. 7A). The funnel plot was roughly symmetric (Fig. 7B). However, Egger’s test in-
dicated that publication bias existed (P = 0.000).
Studies that lasted 24 weeks vs. those that lasted 12 weeks
Five studies [17,19,27,33,40] that assessed the effectiveness of TCM lasted for 24 weeks and
were compared to studies that lasted for 12 weeks. A significant improvement was achieved in
two trials [17,19] that lasted for 24 weeks (SMD 4.59, [2.85–6.33], P (Z)<0.00001) (S4A Fig.)
compared to those that lasted for 12 weeks (WMD 2.45, [2.03, 2.86], P (Z)<0.00001) (Fig. 4A)
with respect to UPDRS III scores. Similarly, a marked improvement in the UPDRS IV score
was presented in the study performed by Kum et al. [25] when the results of 24 week studies
Fig 6. TCM plus western drugs VS. western therapy alone: UPDRS I-IV total score. (A) Forest plot of comparison. NO.1: Pabing Recipe I; NO.3:
Pabing Recipe III; *: H&Y stages 4 with Madopar-taking history; #: H&Y stages 1–3 with Madopar-taking history. (B) Funnel plot of comparison.
doi:10.1371/journal.pone.0118498.g006
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(MD 2.44, [1.42, 3.46], (Z)<0.00001) (S4B Fig.) were compared to those of 12 week studies
(MD 0.32, [0.15–0.49], P (Z) = 0.0002) (Fig. 5A).
Studies with vs. without randomized and placebo-controlled designs
To further examine any differences between the studies having non-blinding/non-placebo-
controlled trials and those with randomized/placebo-controlled designs, we performed a meta-
analysis separately. A higher level of effectiveness was found in studies without randomized
and placebo-controlled designs by the UPDRS-I, UPDRS-II and UPDRS-total scores, but not
by the UPDRS-III and UPDRS-IV scores (S4 Table).
Discussion
Currently, DRT is still considered the “gold standard” for symptomatic treatment of PD due to
the absence of pathological therapies. This systematic review and meta-analysis was designed
to summarize the evidence regarding TCM as an adjunct therapy for PD treatment and has
shown a stabilizing effect in improving PD motor and non-motor symptoms, as well as reduc-
ing the adverse effects of Western medicine. In this meta-analysis, age, gender proportions,
types of TCM, course of disease, concurrent disorders and concomitant treatment were all
taken into account. Due to the flaws in study designs and the small sample sizes of the studies
included in this meta-analysis, the current evidence is insufficient to make a routine recom-
mendation of TCM for PD treatment. However, potentially marked superiorities were shown
by Chinese medicine and acupuncture in improving PD patients’ symptoms, as evidenced by
the UPDRS scores.
Evidence of Chinese Medicines
Of all the Chinese medicines adopted in the trials, Pabing Recipe III/ Five Zhui feng powder/
Bushen Huoxue Tongluo Capsule/ Pabing Recipe I/ Guiling Pa'an Pill have been demonstrated
to be the most efficacious TCMs in improving UPDRS I/II/III/IV/total scores, respectively (S5
Table). Moreover, we defined a good TCM as it could significantly improve PD symptoms
(p<0.05) in at least three aspects of the UPDRS scores. Of all TCMs involved, three TCMs
(Pabing Recipe I, Pabing Recipe III, and Zeng-xiao An-shen Zhi-chan 2), which were applied
in two studies [38,40], satisfied the standard and could be regarded as good TCMs. The studies
lasting for 24 weeks seemed to be more efficacious than those lasting for 12 weeks. However,
authenticity was limited due to the small number of studies involved. More clinical trials with
larger numbers of participants are necessary to verify our conclusions. In the sensitivity analy-
sis, no change was detected in most studies examined here except for the aspect of side effects.
Fig 7. TCM plus western drugs VS. western therapy alone: Side Effect. (A) Forest plot of comparison. (B) Funnel plot of comparison.
doi:10.1371/journal.pone.0118498.g007
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Heterogeneity decreased from 61% to 0% when the study performed by Yuan et al. [36] was ex-
cluded. That was likely because PD patients in the Yuan study were older (69.5 ± 7.81 year)
and had longer disease durations (7.35 ± 1.82 year) than any other participants in other trials
(S1 Table). In fact, TCMs seemed to be well tolerated and had fewer adverse effects in compari-
son with the conventional medicine controls. Despite of the apparently positive findings, it is
still premature to conclude the safety of TCMs for PD treatment because the category and se-
verity of TCMs were not considered in most of the studies that are covered by this meta-
analysis. Detailed records and reporting are strongly recommended.
Evidence of Acupuncture
With respect to the improvements of UPDRS I-IV total scores, acupuncture plus madopar vs.
madopar seemed to be the most efficacious with the highest pooled MD (WMD 10.96, 95%CI
5.85–16.07), followed by TCM plus Western drugs vs. Western therapy (WMD 6.18, 95%CI
5.06–7.31), and TCM vs. placebo (MD 2.57, 95%CI-2.37, 7.51). However, only two trials in-
cluding 117 participants estimated the effect of scalp area and body acupuncture as an adjuvant
therapy to madopar. These trials assessed patients’ symptoms immediately before and after
therapy but whether any initial improvements persisted for a reasonable period of time was un-
known, as no data throughout a follow-up period was available. Collectively, better designs are
needed to make consensus in the field as to what form of acupuncture and acupoint is the most
appropriate to treat PD patients.
Limitations
The therapeutic effects should be interpreted with caution due to the methodological weak-
nesses of the study designs and limitations embodied in the following aspects: (1) Randomiza-
tion All selected trials demonstrated randomization. However, only 13 trials detailed the
randomized grouping methods, while the remaining trials only noted that stochastic grouping
methods were used. (2) Concealment Six trials applied concealment methods including central
telephone randomization systems [31,33], coded containers [25,40], and sealed envelopes
[15,36]. Consequently, subjective factors are prone to increase selection bias because research-
ers tend to assign specific patients into the control or treatment groups. (3) Placebo and Blind-
ing Fourteen studies did not use a placebo as a controlled method, and this might discount the
placebo effects in the control group. Similarly, the 20 trials that did not use the blinding meth-
od tended to induce significant performance and detection bias. (4) Drop-outOnly one [25]
trial adopted the ITT method. Eighteen studies did not mention information regarding drop-
outs. The results from these reports might exaggerate the therapy effects. (5) Heterogeneity All
included trials stated that there were no significant differences at baseline regarding age, gen-
der, and disease course, but seven studies [17,21,23,30,35,38,39] did not report the detailed
data. Moreover, the intervention methods and outcome measures were heterogeneous and
incomplete.
Conclusions
Although many experiments are accompanied by flaws in the design methods, the trials includ-
ed in this meta-analysis do provide potential evidence to indicate that TCM is suitable for
long-term use in PD patients with high acceptance and compliance, especially as an alternative
medicine for routine therapy. Patients receiving TCM add-on therapy exhibited significant su-
periorities in PD symptoms as evidenced by improvements in UPDRS scores. Moreover, TCM
adjuvant therapy was generally safe, well tolerated, and could significantly reduce the side ef-
fects caused by conventional medicine. The effectiveness tended to be more obvious in PD
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patients with longer adjunct treatment durations. However, to clarify the exact effect of TCM
on PD patients, further well-designed studies are needed [41] with the following characteristics:
1) The design should utilize strictly randomized, controlled, double-blind methods; patients
should be selected objectively with standard eligibility criteria to reduce the influence of partici-
pants, interventions, and outcomes measures, minimizing selective bias, performance bias, and
detection bias. 2) Sample sizes should be expanded based on corresponding design formulas. 3)
The follow-up should be prolonged to detect a long-term effect. An inadequate follow-up dura-
tion in individual trials may significantly influence TCM efficacy. Moreover, laboratory exami-
nations are essential to determine the potential side effects of treatment. 4) Non-motor
symptoms of PD should be examined, as the majority of trials are focused on motor symptoms.
Moreover, Tai Chi and acupuncture have been shown to markedly improve UPDRS-III scores,
selected gait initiation parameters or gait performance, as well as reduce the risk of falling in el-
derly and frail individuals [42–46].
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